BioAge Labs Inc.(BIOA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BIOA BioAge Labs Inc.

Closed 10-17 16:00:00 EDT

22.99

-1.18

-4.88%

盘后23.00

+0.01+0.04%

18:49 EDT

High24.20	Low22.50	Vol357.87K
Open24.20	D1 Closing24.17	Amplitude7.03%
Mkt Cap785.50M	Tradable Cap241.39M	Total Shares34.17M
T/O8.25M	T/O Rate3.41%	Tradable Shares10.50M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BIOA","market":"US","secType":"STK","nameCN":"BioAge Labs Inc.","latestPrice":22.99,"timestamp":1729195200000,"preClose":24.17,"halted":0,"volume":357871,"hourTrading":{"tag":"盘后","latestPrice":23,"preClose":22.99,"latestTime":"18:49 EDT","volume":902,"amount":20835.86,"timestamp":1729205359249},"delay":0,"floatShares":10500000,"shares":34167200,"eps":0,"marketStatus":"Closed","change":-1.18,"latestTime":"10-17 16:00:00 EDT","open":24.2,"high":24.2,"low":22.5,"amount":8247719.451117001,"amplitude":0.070335,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1729238400000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":1727323200000,"exchange":"NASDAQ","adjPreClose":24.17,"preHourTrading":{"tag":"盘前","latestPrice":24.91,"preClose":24.17,"latestTime":"08:54 EDT","volume":20,"amount":492.32002,"timestamp":1729169699722},"postHourTrading":{"tag":"盘后","latestPrice":23,"preClose":22.99,"latestTime":"18:49 EDT","volume":902,"amount":20835.86,"timestamp":1729205359249},"volumeRatio":0.906392},"requestUrl":"/m/hq/s/BIOA/wiki","defaultTab":"wiki","newsList":[{"id":"2476784111","title":"Prediction: These 2 Stocks Could Soar in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2476784111","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476784111?lang=en_us&edition=fundamental","pubTime":"2024-10-17 21:45","pubTimestamp":1729172700,"startTime":"0","endTime":"0","summary":"The key word here is \"could.\"","market":"fut","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F793607%2Fresearch-scientists-drugs-pharma-biotech.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F793607%2Fresearch-scientists-drugs-pharma-biotech.jpg&op=resize&w=165&h=104"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com/investing/2024/10/17/prediction-these-2-stocks-could-soar-in-2025/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["RXRX","BK4539","BK4548","BK4139","IPO","BK4007","BIOA"],"gpt_icon":0},{"id":"2475856303","title":"Interested in Weight Loss Stocks Besides Novo Nordisk and Eli Lilly? You Might Want To Check Out This New IPO Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2475856303","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475856303?lang=en_us&edition=fundamental","pubTime":"2024-10-13 02:31","pubTimestamp":1728757860,"startTime":"0","endTime":"0","summary":"BioAge Labs is the latest pharmaceutical company looking to make waves in the weight loss realm.","market":"fut","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F793569%2Fgettyimages-1166581794.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F793569%2Fgettyimages-1166581794.jpg&op=resize&w=165&h=104"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com/investing/2024/10/12/interested-in-weight-loss-stocks-besides-novo-nord/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4585","IE0002141913.USD","LU0708995401.HKD","LU0114720955.EUR","LU0079474960.USD","BIOA","NVO","LU0354030511.USD","LU0256863811.USD","LU0198837287.USD","LU1023059063.AUD","LU1093756168.USD","IE00BFTCPJ56.SGD","LU0882574055.USD","LU0289739699.SGD","LU0471298694.HKD","LU0820561818.USD","LU0094547139.USD","LU1035775433.USD","LU0466842654.USD","LU1061106388.HKD","LU1093756325.SGD","GB00BDT5M118.USD","LU0122379950.USD","LU0882574139.USD","IE0004445239.USD","LU0943347566.SGD","IE00B1BXHZ80.USD","IE00BJLML261.HKD","LU0096364046.USD","LU0109391861.USD","LU0689472784.USD","LU0006306889.USD","LU0097036916.USD","LU0058720904.USD","IE00BJT1NW94.SGD","LU1069344957.HKD","LU0820561909.HKD","LU0385154629.USD","IE00BKVL7J92.USD","LU0354030438.USD","LLY","LU0061475181.USD","IE0009355771.USD","BK4007","LU1057294990.SGD","IPO","IE00BJJMRZ35.SGD","BK4581","BK4532"],"gpt_icon":1},{"id":"2473452908","title":"RA Capital Management, L.P. Acquires New Stake in Bioage Labs Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2473452908","media":"GuruFocus.com","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473452908?lang=en_us&edition=fundamental","pubTime":"2024-10-08 09:10","pubTimestamp":1728349827,"startTime":"0","endTime":"0","summary":"On September 27, 2024, RA Capital Management, L.P., a prominent investment firm, made a significant move in the biopharmaceutical sector by acquiring 2,210,589 shares of Bioage Labs Inc . This transaction, valued at $21 per share, marks a new holding for the firm, reflecting a strategic investment in the healthcare industry. The acquisition not only diversifies RA Capital's portfolio but also underscores its commitment to investing in innovative companies tackling major healthcare challenges.Based in Boston, RA Capital Management, L.P. is renowned for its focus on healthcare and financial services sectors. With a robust portfolio that includes top holdings like Ascendis Pharma AS  and Rhythm Pharmaceuticals Inc , the firm manages an equity portfolio worth approximately $7.56 billion. RA Capital's investment philosophy emphasizes substantial engagement in sectors that promise significant technological or therapeutic advancements.The acquisition of a 0.61% position in Bioage Labs by RA C","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/JTt5bo0JSKtQ3XtJrY3fJQ--~B/aD05MDI7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/9802aef1fe4cb0ac29db2bff39d71eb6","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/JTt5bo0JSKtQ3XtJrY3fJQ--~B/aD05MDI7dz0xMjQyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/us.finance.gurufocus/9802aef1fe4cb0ac29db2bff39d71eb6"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ra-capital-management-l-p-011027241.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNQmain","BIOA","BK4588","TQQQ","SQQQ","LU0109394709.USD","RYTM","ASND","QID","BK4139",".IXIC","NQmain","RA","PSQ","LU0889565916.HKD","QLD","BK4585","LU0320765992.SGD"],"gpt_icon":1},{"id":"2473161087","title":"Regeneron co-founder warns of harms from weight-loss drugs: FT","url":"https://stock-news.laohu8.com/highlight/detail?id=2473161087","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473161087?lang=en_us&edition=fundamental","pubTime":"2024-10-06 22:29","pubTimestamp":1728224971,"startTime":"0","endTime":"0","summary":"The co-founder of biotech firm Regeneron Pharmaceuticals (NASDAQ:REGN) said in a newspaper interview that popular weight-loss drugs could be harmful to people who lose too much muscle mass that’s seen","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1498835905/image_1498835905.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1498835905/image_1498835905.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4156605-regeneron-co-founder-warns-of-harms-from-weight-loss-drugs-ft","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["IE00BJLML261.HKD","BK4534","IE0002141913.USD","IE00BZ1G4Q59.USD","BK4533","LU0289739699.SGD","LU1061106388.HKD","LU0061475181.USD","LLY","LU0006306889.USD","LU0079474960.USD","LU0708995401.HKD","LU0943347566.SGD","LU0882574055.USD","IE00B1BXHZ80.USD","GB00BDT5M118.USD","LU0820561909.HKD","LU1093756168.USD","LU0320765992.SGD","IE0004445239.USD","LU0053666078.USD","LU1093756325.SGD","LU2089984988.USD","LU0354030511.USD","LU1023059063.AUD","LU2362541273.HKD","LU1057294990.SGD","LU2362541513.USD","BK4581","NONOF","NVO","IE00BJJMRZ35.SGD","LU2362540622.SGD","BIOA","IE00BK4W5L77.USD","LU0109391861.USD","LU2468319806.SGD","LU0354030438.USD","IE00BJT1NW94.SGD","LU0114720955.EUR","REGN","LU1035775433.USD","BK4532","LU0096364046.USD","LU0256863811.USD","LU0471298694.HKD","IE00BK4W5M84.HKD","LU0094547139.USD","LU0058720904.USD","LU0122379950.USD"],"gpt_icon":0},{"id":"2473227976","title":"3 Reasons to Buy BioAge Labs Stock Hand Over Fist in October","url":"https://stock-news.laohu8.com/highlight/detail?id=2473227976","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2473227976?lang=en_us&edition=fundamental","pubTime":"2024-10-05 19:15","pubTimestamp":1728126900,"startTime":"0","endTime":"0","summary":"There's a chance that its lead candidate could become one of the top drugs ever.","market":"us","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F792597%2Fscientist-gestures-to-diagram-on-whiteboard.jpg&op=resize&w=165&h=104","type":0,"news_type":0,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F792597%2Fscientist-gestures-to-diagram-on-whiteboard.jpg&op=resize&w=165&h=104"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.fool.com/investing/2024/10/05/3-reasons-to-buy-bioage-labs-stock-hand-over-fist/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["IPO","VC","BK4124","BIOA","LU1815336091.USD","LU0757428866.USD"],"gpt_icon":0},{"id":"2472533467","title":"BioAge Labs Raises $238.3 Million From IPO, Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2472533467","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472533467?lang=en_us&edition=fundamental","pubTime":"2024-10-02 05:22","pubTimestamp":1727817726,"startTime":"0","endTime":"0","summary":"BioAge Labs  said Tuesday it closed its upsized initial public offering of 12.65 million shares and a concurrent private offering of 588,888 shares at $18 apiece for gross proceeds of roughly $238.3 million.Shares of the biopharmaceutical company debuted on Nasdaq on Sept. 26.Price: 20.10, Change: -0.15, Percent Change: -0.74","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NQmain","BIOA"],"gpt_icon":0},{"id":"2472587563","title":"BioAge Labs Announces Closing of Initial Public Offering, Full Exercise of Underwriters’ Option to Purchase Additional Shares and Closing of the Concurrent Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2472587563","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472587563?lang=en_us&edition=fundamental","pubTime":"2024-10-02 04:30","pubTimestamp":1727814600,"startTime":"0","endTime":"0","summary":"RICHMOND, Calif., Oct.  01, 2024  (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (“BioAge”) (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic di","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/01/2956605/0/en/BioAge-Labs-Announces-Closing-of-Initial-Public-Offering-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares-and-Closing-of-the-Concurrent-Private-Placement.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1791807156.HKD","LU0314104364.USD","LU0320765646.SGD","BIOA","LU2237443382.USD","LU2237443549.SGD","BK4581","LU2357305700.SGD","LU2237443895.HKD","BK4533","IE00B19Z3B42.SGD","LU1074936037.SGD","BK4534","IE0034235188.USD","LU0098860793.USD","IE00BFXG1179.USD","IE00BSNM7G36.USD","LU1720051108.HKD","LU2237443465.HKD","BK4552","BK4139","IE00B19Z3581.USD","LU2237443978.SGD","LU1989772923.USD","BK4588","BK4585","IE00BKVL7J92.USD","IE0004086264.USD","LU0971096721.USD","LU1162221912.USD","LU2237443622.USD","VIRI","LU2237438978.USD","BK4504","IE0004091025.USD","BK4127","IE00BZ1G4Q59.USD","LU1548497426.USD","LU1720051017.SGD","BK4550","LU0267386448.USD","LU0106831901.USD","LU1363072403.SGD","LU0225283273.USD","LU1668664300.SGD","LU1989772840.SGD","IE0002270589.USD"],"gpt_icon":0},{"id":"2472333195","title":"BioAge Labs: Weighing The Risks And Rewards Of A Biotech Revival","url":"https://stock-news.laohu8.com/highlight/detail?id=2472333195","media":"seekingalpha","labels":["analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472333195?lang=en_us&edition=fundamental","pubTime":"2024-10-01 00:36","pubTimestamp":1727714212,"startTime":"0","endTime":"0","summary":"Only 19, with significant price drops. However, recently, things have started to improve. The Federal Reserve has started lowering interest rates, making borrowing cheaper again. This change, along with other signs of recovery in the biotech sector, has led to a rise in IPOs. Since bottoming out in October 2023, biotech stocks, tracked by the SPDR S&P Biotech ETF , have surged by 53%, beating the S&P 500’s","market":"fut","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/57532966/image_57532966.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/57532966/image_57532966.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4724253-bioage-labs-weighing-the-risks-and-rewards-of-a-biotech-revival","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BIOA"],"gpt_icon":0},{"id":"2471839799","title":"Opening Day: Obesity drug developer BioAge makes Nasdaq debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2471839799","media":"TIPRANKS","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2471839799?lang=en_us&edition=fundamental","pubTime":"2024-09-29 18:20","pubTimestamp":1727605212,"startTime":"0","endTime":"0","summary":"Shares of BioAge Labs opened for trading this week, with the company planning to use the proceeds of its initial public offering to take its lead o...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/opening-day-obesity-drug-developer-bioage-makes-nasdaq-debut?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/opening-day-obesity-drug-developer-bioage-makes-nasdaq-debut?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2210150020.SGD","BIOA","TQQQ","IE00BKPKM429.USD","IE00B64PRP62.GBP","QID","PSQ","BK4585","NQmain","LU2210149790.SGD","LU2095319765.USD","BK4112","QLD","BK4588","SQQQ","NDAQ","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","MNQmain",".IXIC"],"gpt_icon":0},{"id":"2470005339","title":"Biotech IPOs return as sector recovers after funding overhang","url":"https://stock-news.laohu8.com/highlight/detail?id=2470005339","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470005339?lang=en_us&edition=fundamental","pubTime":"2024-09-28 02:49","pubTimestamp":1727462957,"startTime":"0","endTime":"0","summary":"Biotech IPOs are making a comeback alongside the sector’s recent gains as funding constraints fueled by record-high interest rates start to ease. Biotechs, generally considered a risky bet by investor","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1993053702/image_1993053702.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1993053702/image_1993053702.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4154203-biotech-ipos-return-sector-recovers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4581","BK4007","BIOA","BK4585","BCAX","XBI","BK4588","MBX","ZBIO","BK4139"],"gpt_icon":0},{"id":"1163429423","title":"Stock Track | BioAge Labs Soars on Promising Obesity Drug and Successful IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1163429423","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1163429423?lang=en_us&edition=fundamental","pubTime":"2024-09-27 21:36","pubTimestamp":1727444178,"startTime":"0","endTime":"0","summary":"Shares of BioAge Labs Inc.  continued their meteoric rise on Thursday, soaring 6.36% in pre-market trading after a blockbuster debut on the Nasdaq the previous day. The clinical-stage biopharmaceutical company's stock has captured the attention of investors eager to get in early on its promising lead product candidate, azelaprag.On Wednesday, BioAge Labs' initial public offering  was met with overwhelming demand, with the stock skyrocketing 32% on its first trading day. The company raised $198 m","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["BIOA"],"gpt_icon":0},{"id":"1176835075","title":"Stock Track | BioAge Labs Surges in Pre-Market Trading After Blockbuster IPO for Obesity Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1176835075","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176835075?lang=en_us&edition=fundamental","pubTime":"2024-09-27 20:56","pubTimestamp":1727441799,"startTime":"0","endTime":"0","summary":"Shares of BioAge Labs Inc.  soared 5.73% in pre-market trading on Thursday, extending their stellar rally after the clinical-stage biopharmaceutical company made a blockbuster debut on the Nasdaq the previous day.On Wednesday, BioAge Labs' initial public offering  was met with overwhelming investor demand, with the stock skyrocketing 32% on its first trading day. The company raised $198 million by offering 11 million shares at $18 apiece, pricing above the expected range in a sign of strong inte","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["BIOA"],"gpt_icon":0},{"id":"1143233911","title":"Stock Track | BioAge Labs Soars 32% in Nasdaq Debut on Strong Demand for Obesity Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=1143233911","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143233911?lang=en_us&edition=fundamental","pubTime":"2024-09-27 09:12","pubTimestamp":1727399560,"startTime":"0","endTime":"0","summary":"Shares of BioAge Labs Inc.  soared 32% in their Nasdaq debut on Wednesday, as investors flocked to the clinical-stage biopharmaceutical company developing a promising new treatment for obesity.BioAge Labs priced its upsized initial public offering  of 11 million shares at $18 per share, raising $198 million in proceeds. The stock opened at $22.50, a staggering 25% premium to the IPO price, reflecting robust investor demand for the offering.The successful IPO comes against the backdrop of a surgi","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["BIOA"],"gpt_icon":0},{"id":"2470750645","title":"BioAge Labs, An Obesity Newcomer And Eli Lilly Partner, Rallies 28% On Upsized IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2470750645","media":"Blockhead","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470750645?lang=en_us&edition=fundamental","pubTime":"2024-09-27 01:18","pubTimestamp":1727371134,"startTime":"0","endTime":"0","summary":"BioAge Labs stock rallied Thursday on the company's upsized IPO — reflecting enthusiasm for its approach to obesity treatments.","market":"us","thumbnail":"https://www.investors.com/wp-content/uploads/2017/10/Stock-biotechLab-01-adobe-150x150.jpg","type":0,"news_type":0,"thumbnails":["https://www.investors.com/wp-content/uploads/2017/10/Stock-biotechLab-01-adobe-150x150.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.investors.com/news/technology/bioage-labs-obesity-treatment-eli-lilly-partner/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"investor_business_daily_highlight","symbols":["BK4533","LU0471298694.HKD","IE0009355771.USD","LU0289739699.SGD","GPCR","LU0466842654.USD","LU1061106388.HKD","LU0006306889.USD","LU0096364046.USD","LU0820561909.HKD","LU0058720904.USD","LU0354030438.USD","LU0943347566.SGD","LU0061475181.USD","LU0882574139.USD","BK4585","IE0004445239.USD","LU1057294990.SGD","IE00BJJMRZ35.SGD","LU0708995401.HKD","BK4588","IE00BK4W5L77.USD","BK4534","BIOA","LU0097036916.USD","LU0689472784.USD","BK4516","GB00BDT5M118.USD","LU0094547139.USD","LU0672654240.SGD","LU0114720955.EUR","LU0109391861.USD","LU0079474960.USD","LU0256863811.USD","BK4007","LU0354030511.USD","LLY","IE00BJT1NW94.SGD","LU1069344957.HKD","IE00B1BXHZ80.USD","LU0122379950.USD","IE00BJLML261.HKD","LU0385154629.USD","LU1551013342.USD","LU1280957306.USD","LU0882574055.USD","LU1035775433.USD","LU1023059063.AUD","IE0002141913.USD","IE00BK4W5M84.HKD"],"gpt_icon":1},{"id":"2470875733","title":"GRAPHIC-US IPOs set to extend recovery after staging a solid comeback","url":"https://stock-news.laohu8.com/highlight/detail?id=2470875733","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470875733?lang=en_us&edition=fundamental","pubTime":"2024-09-27 00:55","pubTimestamp":1727369743,"startTime":"0","endTime":"0","summary":"By Niket  Nishant and Manya Saini      Sept 26 (Reuters) - The U.S. IPO market has bounced back strongly in 2024 after a nearly two-year dry spell, driven by receding recession fears and a searing ral","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4224","BK4185","LINE","BIOA","CON","RDDT"],"gpt_icon":0},{"id":"2470757889","title":"BioAge posts double-digit percentage gain after IPO; natural-gas producer BKV rises in debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2470757889","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470757889?lang=en_us&edition=fundamental","pubTime":"2024-09-27 00:50","pubTimestamp":1727369400,"startTime":"0","endTime":"0","summary":"Obesity-drug developer BioAge jumps nearly 30% after its IPO, while Texas-based Barnett Shale driller BKV posts more modest gain. Obesity-drug developer BioAge Labs Inc. gained nearly 30% after its initial public offering on Thursday, while natural-gas producer BKV Inc.'s rose about 3% over its $18 IPO price.BioAge  stock opened at $22.50 and recently changed hands at $22.86 a share for a gain of nearly 30% over its $18-a-share IPO price.BKV's stock  opened at $18.55 a share, above its $18 IPO price, and traded at $18.51 a share at midday.Richmond, Calif.-based BioAge Labs  priced 11 million shares at $18 each, the middle of its $17 to $19 price range.The company raised $198 million with underwriters Goldman Sachs, Morgan Stanley, Jefferies and Citigroup.BioAge defines itself as a clinical-stage biopharmaceutical company developing drugs for metabolic diseases, such as obesity, by targeting human aging.Denver-based BKV's IPO priced below its estimated range of $19 to $21.BKV Chief Exec","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","LU0971096721.USD","LU0106831901.USD","LU0267386448.USD","BK4581","BK4127","BKV","LU1989772840.SGD","LU1989772923.USD","LU1720051017.SGD","LU0098860793.USD","BK4534","BK4504","LU1720051108.HKD","BIOA","LU0225283273.USD","IE00BZ1G4Q59.USD","LU0320765646.SGD","LU1074936037.SGD","LU1363072403.SGD","BK4585","LU1162221912.USD","LU2357305700.SGD","LU1548497426.USD","BK4588","IE00BKVL7J92.USD","LU1668664300.SGD"],"gpt_icon":0},{"id":"2470475264","title":"BioAge Labs Shares Surge on Nasdaq Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2470475264","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470475264?lang=en_us&edition=fundamental","pubTime":"2024-09-27 00:40","pubTimestamp":1727368809,"startTime":"0","endTime":"0","summary":"BioAge Labs  shares were up almost 28% in recent trading Thursday after debuting on Nasdaq, higher than the initial public offering price of $18 per share.The stock is trading under the ticker symbol \"BIOA.\"The company is offering 11 million shares in the IPO for gross proceeds of $198 million and has granted underwriters an overallotment option of additional 1.7 million shares.Price: 23.01, Change: +5.01, Percent Change: +27.83","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4112","IE00B3QW5Z07.USD","BIOA","LU2095319765.USD",".IXIC","LU2210150020.SGD","IE00BKPKM429.USD","LU2210149790.SGD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","NDAQ","BK4585","NQmain"],"gpt_icon":0},{"id":"2470189754","title":"UPDATE 1-BioAge valued at $758 mln in debut as investors bet on weight-loss drug frenzy","url":"https://stock-news.laohu8.com/highlight/detail?id=2470189754","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470189754?lang=en_us&edition=fundamental","pubTime":"2024-09-27 00:23","pubTimestamp":1727367798,"startTime":"0","endTime":"0","summary":"(Adds details throughout)      Sept 26 (Reuters) - Shares of BioAge Labs    opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer agains","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIOA"],"gpt_icon":0},{"id":"2470754536","title":"Weight-loss drug developer BioAge valued at $758 mln in Nasdaq debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2470754536","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470754536?lang=en_us&edition=fundamental","pubTime":"2024-09-27 00:16","pubTimestamp":1727367407,"startTime":"0","endTime":"0","summary":"Sept 26  - Shares of BioAge Labs    opened 25% above their initial public offering price in their Nasdaq debut on Thursday, valuing the weight-loss drug developer at $757.5 million. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","IE00B3QW5Z07.USD",".IXIC","NDAQ","LU2210150020.SGD","BK4585","LU2210149790.SGD","BK4112","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4588","BIOA","LU2095319765.USD"],"gpt_icon":0},{"id":"1132193437","title":"Stock Track | BioAge Labs Soars 25% After Successful $198 Million IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=1132193437","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132193437?lang=en_us&edition=fundamental","pubTime":"2024-09-27 00:16","pubTimestamp":1727367393,"startTime":"0","endTime":"0","summary":"Shares of BioAge Labs Inc.  surged 25% on Wednesday after the clinical-stage biopharmaceutical company priced its upsized initial public offering , raising $198 million by selling 11 million shares at $18 each.The Richmond, California-based company is looking to capitalize on the surging popularity of weight-loss drugs, which are expected to become a $150 billion market by the early 2030s. BioAge is developing azelaprag, a pill intended to be used in combination with leading weight-loss treatmen","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["BIOA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://bioagelabs.com","stockEarnings":[{"period":"1week","weight":0.2061},{"period":"1month","weight":0.3428},{"period":"ytd","weight":0.3428}],"compareEarnings":[{"period":"1week","weight":0.0088},{"period":"1month","weight":0.0344},{"period":"3month","weight":0.0535},{"period":"6month","weight":0.1758},{"period":"1year","weight":0.3353},{"period":"ytd","weight":0.2249}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":" ","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.008123},{"month":2,"riseRate":0.4,"avgChangeRate":-0.16094},{"month":3,"riseRate":0.2,"avgChangeRate":-0.091972},{"month":4,"riseRate":0.4,"avgChangeRate":-0.044244},{"month":5,"riseRate":0,"avgChangeRate":-0.19738},{"month":6,"riseRate":0.25,"avgChangeRate":0.003055},{"month":7,"riseRate":0.4,"avgChangeRate":-0.005696},{"month":8,"riseRate":0.4,"avgChangeRate":-0.229124},{"month":9,"riseRate":0.6,"avgChangeRate":0.004924},{"month":10,"riseRate":0.8,"avgChangeRate":0.181962},{"month":11,"riseRate":0.6,"avgChangeRate":0.056827},{"month":12,"riseRate":0.2,"avgChangeRate":-0.087267}],"exchange":"NASDAQ","name":"BioAge Labs Inc.","nameEN":"BioAge Labs Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.0","shortVersion":"4.29.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioAge Labs Inc.(BIOA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BioAge Labs Inc.(BIOA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BioAge Labs Inc.,BIOA,BioAge Labs Inc.股票,BioAge Labs Inc.股票老虎,BioAge Labs Inc.股票老虎国际,BioAge Labs Inc.行情,BioAge Labs Inc.股票行情,BioAge Labs Inc.股价,BioAge Labs Inc.股市,BioAge Labs Inc.股票价格,BioAge Labs Inc.股票交易,BioAge Labs Inc.股票购买,BioAge Labs Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioAge Labs Inc.(BIOA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BioAge Labs Inc.(BIOA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}